Cold Agglutinin Disease Market is Projected to Witness Significant Growth by 2036 Owing to Rising Disease Awareness and Continued Adoption of Targeted Complement Inhibition | DelveInsight

The Cold Agglutinin Disease (CAD) market is witnessing steady growth, driven by increasing disease awareness, improving diagnosis rates, growing adoption of targeted complement inhibitors, and rising demand for therapies that reduce hemolysis and improve patient outcomes. Expanding access to disease-specific treatments, favorable reimbursement policies, and advances in rare disease management are expected to further strengthen the market during the forecast period.
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Cold Agglutinin Disease (CAD) Market Insights, Epidemiology, and Market Forecast - 2036." This comprehensive report provides an in-depth understanding of Cold Agglutinin Disease, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Cold Agglutinin Disease Market

*
The market size for Cold Agglutinin Disease (CAD) in the seven major markets is expected to grow significantly by 2036.

*
The United States accounted for the highest Cold Agglutinin Disease market size among the 7MM in 2025, while Spain accounted for the lowest number of cases.

*
According to DelveInsight's analysis, the total prevalent cases of CAD in the 7MM were approximately 15,000 in 2025 and are expected to increase during the forecast period (2026-2036).

*
According to the National Organization for Rare Disorders (NORD) (2023), CAD most commonly affects individuals between 40 and 80 years of age, with the median age at symptom onset around 65 years.

*
According to NORD, Cold Agglutinin Disease is nearly twice as prevalent in women as in men, and individuals with conditions associated with CAD have an increased likelihood of developing the disease.

*
According to Berentsen et al., CAD accounts for approximately 15-25% of autoimmune hemolytic anemia (AIHA) cases and primarily affects middle-aged and older adults.

*
ENJAYMO (sutimlimab-jome), developed by Sanofi, is currently the first and only FDA-approved therapy specifically indicated for the treatment of Cold Agglutinin Disease by reducing complement-mediated hemolysis.

*
In October 2024, Recordati entered into an agreement with Sanofi to acquire the worldwide rights to ENJAYMO for USD 825 million, strengthening its rare disease portfolio.

*
The current CAD pipeline remains limited, with no clinical-stage pipeline assets, highlighting substantial unmet medical needs and opportunities for future innovation.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/cold-agglutinin-disease-cad-market [https://www.delveinsight.com/sample-request/cold-agglutinin-disease-cad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Key Factors Driving the Cold Agglutinin Disease Market

Increasing Disease Awareness and Improved Diagnosis

Growing awareness among healthcare professionals, advances in diagnostic techniques, and improved recognition of autoimmune hemolytic disorders are leading to earlier diagnosis of Cold Agglutinin Disease. Enhanced disease recognition is expected to increase the diagnosed patient pool and support market growth.

Growing Adoption of Targeted Complement Inhibitors

The introduction of ENJAYMO (sutimlimab-jome) has transformed the treatment landscape by specifically targeting the classical complement pathway responsible for hemolysis in CAD. Increasing physician confidence and wider availability of disease-specific therapy are expected to drive continued market expansion.

Rising Need for Effective Rare Disease Therapies

Despite recent therapeutic advances, there is currently no cure for CAD, and many patients continue to rely on supportive care and off-label therapies. The significant unmet medical need, coupled with increasing investment in rare disease treatment, is expected to support future market growth.

Cold Agglutinin Disease Competitive Landscape

The current Cold Agglutinin Disease treatment landscape is led by ENJAYMO (sutimlimab-jome) from Sanofi, the first and only approved therapy specifically indicated for CAD. ENJAYMO is a humanized monoclonal antibody that selectively inhibits C1s within the classical complement pathway, preventing complement-mediated destruction of red blood cells and reducing hemolysis. Since its approval by the US FDA in February 2022, the therapy has established a new standard of care for adults with CAD. Subsequent approvals in Europe (November 2022) and Japan (June 2022) have further expanded its global availability.

Although current disease management continues to include off-label therapies such as rituximab, bendamustine, fludarabine, bortezomib, and supportive interventions including plasmapheresis, the clinical pipeline remains limited, with no emerging therapies currently in clinical development. This presents significant opportunities for pharmaceutical companies developing novel disease-modifying treatments capable of addressing the substantial unmet needs in the Cold Agglutinin Disease market.

Discover more about therapies set to grab major Cold Agglutinin Disease market share @ Cold Agglutinin Disease Treatment Landscape [https://www.delveinsight.com/sample-request/cold-agglutinin-disease-cad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Cold Agglutinin Disease Market

*
In October 2024, Recordati entered into an agreement with Sanofi to acquire the worldwide rights to ENJAYMO for USD 825 million, strengthening its rare disease portfolio and expanding access to the only approved disease-specific therapy for Cold Agglutinin Disease.

*
In January 2023, the US FDA expanded the approval of ENJAYMO (sutimlimab-jome) to include the treatment of hemolysis in adults with Cold Agglutinin Disease, irrespective of a history of blood transfusions.

*
In November 2022, the European Commission approved ENJAYMO for the treatment of hemolytic anemia in adult patients with Cold Agglutinin Disease.

*
In June 2022, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ENJAYMO for the treatment of Cold Agglutinin Disease, further expanding its global availability.

*
The current Cold Agglutinin Disease pipeline remains limited, with no assets currently in clinical development, highlighting a substantial unmet need for additional disease-modifying therapies despite recent advances in complement inhibition.

What is Cold Agglutinin Disease?

Cold Agglutinin Disease (CAD) is a rare autoimmune hemolytic anemia in which the immune system mistakenly attacks red blood cells, particularly when exposed to cold temperatures. Cold-reactive autoantibodies cause red blood cells to agglutinate (clump together) and activate the classical complement pathway, resulting in hemolysis and chronic anemia.

Patients commonly experience symptoms such as fatigue, shortness of breath, acrocyanosis, jaundice, dark urine, and cold-induced circulatory disturbances. Severe complications may include hemolytic anemia, Raynaud's phenomenon, CAD-associated lymphoproliferative disorders, and late-onset malignancies. Diagnosis is established through clinical evaluation, patient history, and laboratory investigations including hemoglobin assessment, hematocrit measurement, and other blood tests. Although there is currently no cure for CAD, treatment aims to reduce hemolysis, alleviate symptoms, prevent complications, and improve patients' quality of life.

Cold Agglutinin Disease Epidemiology Segmentation

The Cold Agglutinin Disease epidemiology section provides insights into the historical and current CAD patient pool and forecasted trends across the seven major markets. The Cold Agglutinin Disease market report provides epidemiological analysis for the study period 2022-2036, segmented into:

*
Total Prevalent Cases of Cold Agglutinin Disease

*
Total Diagnosed Prevalent Cases of Cold Agglutinin Disease

*
Gender-specific Cases of Cold Agglutinin Disease

*
Type-specific Cases of Cold Agglutinin Disease

*
Total Treated Cases of Cold Agglutinin Disease

Scope of the Cold Agglutinin Disease Market Report

*
Therapeutic Assessment: Current marketed and emerging therapies for Cold Agglutinin Disease

*
Cold Agglutinin Disease Market Dynamics: Key market forecast assumptions, pricing trends, analogue assessment, therapy uptake, and market outlook

*
Key Companies: Sanofi, Recordati, and others

*
Key Therapies: ENJAYMO, rituximab, bendamustine, fludarabine, bortezomib, plasmapheresis, and supportive therapies

*
Competitive Intelligence Analysis: SWOT analysis and market opportunity assessment

*
Unmet Needs, KOL Views, Analyst Views, Cold Agglutinin Disease Market Access and Reimbursement

To know more about Cold Agglutinin Disease companies working in the treatment market, visit @ Cold Agglutinin Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/cold-agglutinin-disease-cad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Cold Agglutinin Disease Market Report Introduction

*
Executive Summary for Cold Agglutinin Disease

*
SWOT Analysis of Cold Agglutinin Disease

*
Cold Agglutinin Disease Patient Share (%) Overview at a Glance

*
Cold Agglutinin Disease Market Overview at a Glance

*
Cold Agglutinin Disease Background and Overview

*
Cold Agglutinin Disease Epidemiology and Patient Population

*
Country-Specific Patient Population of Cold Agglutinin Disease

*
Cold Agglutinin Disease Current Treatment and Medical Practices

*
Cold Agglutinin Disease Unmet Needs

*
Cold Agglutinin Disease Emerging Therapies

*
Cold Agglutinin Disease Market Outlook

*
Country-Wise Cold Agglutinin Disease Market Analysis (2022-2036)

*
Cold Agglutinin Disease Market Access and Reimbursement

*
Cold Agglutinin Disease Market Drivers

*
Cold Agglutinin Disease Market Barriers

*
Cold Agglutinin Disease Appendix

*
Cold Agglutinin Disease Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cold-agglutinin-disease-market-is-projected-to-witness-significant-growth-by-2036-owing-to-rising-disease-awareness-and-continued-adoption-of-targeted-complement-inhibition-delveinsight]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.